# **Oncology Clinical Pathways** Acute Promyelocytic Leukemia (APL)

June 2024 - V1.2024







## **Table of Contents**

Presumptive Conditions	3
Acute Promyelocytic Leukemia	4
Acute Promyelocytic Leukemia, Relapsed	5
<u> Molecular Testing Table</u>	6







## **Acute Promyelocytic Leukemia – Presumptive Conditions**

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

<u>Atomic Veterans – Exposure to Ionizing Radiation</u>

• All forms of leukemia, except chronic lymphocytic leukemia


For more information, please visit U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)







#### **Acute Promyelocytic Leukemia**










#### **Acute Promyelocytic Leukemia – Relapsed**



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

<sup>a</sup> Acute Promyelocytic Leukemia all trans retinoic acid (ATRA) should be started even prior to results of confirmatory testing; while awaiting diagnostic confirmation, begin ATRA in any patient with clinical suspicion for APL:

- Auer rods on smear, promyelocytes in excess
- Evidence of coagulopathy (low fibrinogen, bleeding)
- Hypo granular morphology (bilobed nuclei, minimal granules)
- APL-like flow cytometry profile (CD33+, CD34-, HLA-DR-, CD117+)

<sup>b</sup> DIC transfuse cryoprecipitate to keep fibrinogen ≥150 mg/dL and platelet transfusion to keep platelet ≥50,000/mm<sup>3</sup>; FFP can be used in addition for clinical significant bleeding; invasive procedures must be avoided; monitoring of DIC may need to be as frequent as q6-8h in the acute phase

<sup>c</sup> **ATRA** monitor for differentiation syndrome characterized by fever, hypoxia, and often transaminitis; prophylactic prednisone steroids can be used to prevent differentiation syndrome; treatment for differentiation syndrome involves holding ATRA and giving dexamethasone 10 mg every 6 hours until symptoms resolve

<sup>d</sup> Arsenic Trioxide should be monitored with twice weekly EKGs to measure the QTc; baseline EKG for QTc interval assessment, serum electrolytes (K, Ca, Mg) and SCr, LFTs, blood glucose; correct baseline electrolyte abnormalities; pregnancy test is recommended prior to initiation in patients with childbearing potential and patient partners who are of childbearing potential; consider thiamine level in patients at risk for deficiency due to risk of Wernicke encephalopathy; during therapy, maintain K and Mg in normal range; avoid concurrent use of drugs that prolong QTc interval; monitor for differentiation syndrome, neurologic symptoms, and nutritional status

\* Anthracycline Chemotherapy for patients who are not candidates for anthracycline chemotherapy, an alternative regimen is ATRA + arsenic + gemtuzumab ozogamicin

<sup>f</sup>Count Recovery absolute neutrophil count ≥1000/mm<sup>3</sup>, platelets ≥100,000/mm<sup>3</sup>

APL Acute Promyelocytic Leukemia ATO Arsenic Trioxide ATRA All Trans Retinoic Acid CBC Complete Blood Count CNS Central Nervous System DIC Disseminated Intravascular Coagulation FISH Fluorescence In Situ Hybridization INR International Normalized Ratio PCR Polymerase Chain Reaction PT Prothrombin Time aPTT, Activated Partial Thromboplastin Time







### Acute Promyelocytic Leukemia – Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Acute Leukemia (Mixed Phenotype or Undifferentiated Leukemia)	Flow Cytometry	Leukemia/lymphoma panel	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Blood
	Karyotyping	Karyotyping	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Blood
		-5/-5q, -7/-7q, KMT2A, t(8;21) RUNX1::RUNX1T1, t(15;17) PML::RARA, t(16;16) or inv(16) CBFB::MYH11; t(9;22) BCR::ABL1; TP53	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Blood
	Rapid Molecular Tests (<1 week TAT)	FLT3 ITD and TKD, IDH1/2, NPM1 (quantitative preferred), CEBPA (optional)	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Blood
	Somatic NGS	RNA and DNA based CGP	Foundation Medicine	Yes	Bone Marrow Biopsy, Blood





